Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 6/20 | 0.42 |
| ▸ | CTSK | P43235 | 5/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.40 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 3/20 | 0.40 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4368196 | 0.98 | CTSK (0.42) | CTSLCTSKFABP4FABP5CTSS | |
| SCHEMBL23673501 | 0.81 | CTSK (0.37) | CTSKFABP4FABP5 | |
| SCHEMBL2156068 | 0.79 | CTSK (0.66) | CTSLCTSKCTSSCTSB | |
| SCHEMBL31414847 | 0.77 | FABP4 (0.45) | CTSLCTSKFABP4FABP5CTSS | |
| SCHEMBL31414906 | 0.77 | FABP4 (0.45) | CTSLCTSKFABP4FABP5CTSS | |
| SCHEMBL5870313 | 0.75 | ALDH1A1 (0.40) | CTSLCTSKFABP4FABP5ALDH1A1 | |
| SCHEMBL8257823 | 0.75 | ALDH1A1 (0.40) | CTSLCTSKFABP4FABP5ALDH1A1 | |
| SCHEMBL3259891 | 0.73 | LMNA (0.51) | ALDH1A1 | |
| SCHEMBL3259889 | 0.73 | LMNA (0.51) | ALDH1A1 | |
| SCHEMBL4377603 | 0.72 | CTSL (0.35) | CTSLCTSKCTSSCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | TEIJIN PHARMA LIMITED (JP) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291945-A1 | CYSTEINE PROTEASE INHIBITORS | CTSE, SPINT2, CTSF | CTSL 24/4885CTSK 15/4885FABP4 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.